Opthea Ltd

Opthea Ltd

Opthea Ltd, founded in 2018, is a clinical-stage biopharmaceutical company led by CEO Megan Baldwin. The firm originated from research into vascular biology and has since concentrated on ophthalmic therapeutics, specifically targeting the VEGF-C/D pathway for retinal disease treatment. Its sole focus is developing OPT-302, a biologic candidate aimed at wet age-related macular degeneration and diabetic macular edema. The firm employs a direct research-and-development strategy, funding its clinical programs through public equity raises and partnerships rather than licensing its platform. Asset-class mix includes biotech R&D, with stage coverage limited to late-stage clinical development. Opthea has announced collaborations with contract research organizations such as IQVIA (per public filings, 2023) and maintains operations primarily in Australia and the United States. Confirmed geographic footprint includes Melbourne, Australia, and offices in the U.S., though specific locations are not publicly detailed. Team size is not officially disclosed, but the firm reports fewer than 50 employees in public filings. Opthea has raised approximately $500 million through equity offerings since inception (per public filings), with recent funding rounds including a $100 million raise in March 2024. The firm also maintains a partnership with Novartis for non-dilutive funding via a royalty-based arrangement (per Opthea press release, 2024). No adjacent vehicles or philanthropic structures have been identified. Opthea's structural differentiator is its exclusive focus on the VEGF-C/D axis, a pathway distinct from mainstream VEGF-A inhibitors used in current standard-of-care treatments. This narrow therapeutic focus means its success hinges entirely on OPT-302's clinical trial outcomes, creating a high-risk, high-concentration biotech mandate that resembles a venture-stage bet rather than a diversified biotech portfolio.